Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 2, 2004, Pages 51-59

  Barilla, Denise ^a   Prasad, Pratapa ^a   Hubert, Martine ^b   Gumbhir Shah, Kavita ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

^c PharmaConsult Inc   (United States)

Author keywords

Extended release; Fluvastatin; Hypocholesterolaemia; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; FLUINDOSTATIN; LESCOL XL; PARACETAMOL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENDER; HEADACHE; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TABLET FORMULATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIVER; MALE; MIDDLE AGED; TABLETS; TIME FACTORS;

EID: 1842484805     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.378     Document Type: Article

References (17)

1. Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993; 87 (Suppl III): III-45-III-53.
2. Langtry HD, Markham A. Fluvastatin: A review of its use in lipid disorders. Drugs 1999; 57: 583-606.
3. Plosker GL, Wagstaff AJ. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolemia. Drugs 1996; 51: 433-459.
4. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.
5. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998; 31: 773-778.
6. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630-638.
7. Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6: 375S-382S.
8. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348-371.
9. Appel S, Dingemanse J. Clinical pharmacokinetics of fluvastatin with reference to other HMG-CoA reductase inhibitors. Drugs Today 1996; 32 (Suppl A): 37-55.
10. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences. Clin Pharmacokinet 1997; 32: 403-425.
11. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40: 263-281.
12. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73: 3D-11D.
13. Siekmeier R, Lattke P, Mix C, Park JW, Jaross W. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. J Cardiovasc Pharmacol Ther 2001; 6: 137-145.
14. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743-759.
15. Ballantyne CM, Pazzucconi F, Pinto X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis. Clin Ther 2001; 23: 177-192.
16. Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hyphercholesterolemia. J Cardiovasc Pharmacol 2001; 37: 502-511.
17. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994; 73: 12D-17D.